Proteomics-based identification of human acute leukemia antigens that induce humoral immune response.
The identification of panels of tumor antigens that elicit an antibody response may have utility in cancer screening, diagnosis, and establishing prognosis. Until now, autoimmunity in cancer has been mainly revealed in solid tumors. The aim of this study was to apply the proteomic approach to the identification of proteins that commonly elicit a humoral response in acute leukemia (AL). Sera from 21 newly diagnosed patients with AL, 20 patients with solid tumors, and 22 noncancer controls were analyzed for antibody-based reactivity against AL proteins resolved by two-dimensional electrophoresis. As a result, autoantibody against a protein identified by mass spectrometry as Rho GDP dissociation inhibitor 2 was detected in sera from 15 of 21 patients with AL (71%). By contrast, such antibody was detected in sera from one of 20 patients with solid tumors (5%) and one of 22 noncancer controls (4.5%). Five other protein autoantibodies were also found in AL patients with a high frequency and constituted the major target antigens of the AL autoimmune response. The findings of autoantibodies against Rho GDP dissociation inhibitor 2 and other proteins in sera of patients with AL suggest that the proteomic approach we have implemented may have utility for the development of a serum-based assay for AL screening and diagnosis.
Cui
Jiu-wei
JW
Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing and the Department of Hematology and Oncology, the First Clinical Hospital of Jilin University, Changchun 130021, China.
Li
Wei-hua
WH
Wang
Jie
J
Li
Ai-ling
AL
Li
Hui-yan
HY
Wang
Hong-xia
HX
He
Kun
K
Li
Wei
W
Kang
Li-hua
LH
Yu
Ming
M
Shen
Bei-fen
BF
Wang
Guan-jun
GJ
Zhang
Xue-min
XM
D000293:Adolescent; D000328:Adult; D000595:Amino Acid Sequence; D000917:Antibody Formation / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D016022:Case-Control Studies; D020730:Guanine Nucleotide Dissociation Inhibitors / Q000032:analysis / Q000737:chemistry; D006801:Humans; D007938:Leukemia / Q000276:immunology* / Q000378:metabolism*; D013058:Mass Spectrometry; D008875:Middle Aged; D008969:Molecular Sequence Data; D040901:Proteomics; D015203:Reproducibility of Results; D025521:Tumor Suppressor Proteins / Q000032:analysis / Q000737:chemistry; D062947:rho-Specific Guanine Nucleotide Dissociation Inhibitors
D000951:Antigens, Neoplasm; D001323:Autoantibodies; D020730:Guanine Nucleotide Dissociation Inhibitors; D025521:Tumor Suppressor Proteins; D062947:rho-Specific Guanine Nucleotide Dissociation Inhibitors